Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2

키워드

참고문헌 (200)

1. "WHO Coronavirus (COVID-19) Dashboard"[URL]
2. Yurkovetskiy L, "Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant", Cell, 183, pp.739~751 (2020)
3. Harvey WT, "SARS-CoV-2 variants, spike mutations and immune escape", Nat. Rev. Microbiol, 19, pp.409~424 (2021)
4. Huang X, "Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme", J. Virol, 89, pp.7202~7213 (2015)
5. Krempl C, "Analysis of cellular receptors for human coronavirus OC43", Adv. Exp. Med. Biol, 380, pp.371~374 (1995)
6. Schultze B, "Recognition of N-acetyl-9-O-acetylneuraminic acid by bovine coronavirus and hemagglutinating encephalomyelitis virus", Adv. Exp. Med. Biol, 342, pp.299~304 (1993)
7. Maginnis MS, "Virus-receptor interactions : The key to cellular invasion", J. Mol. Biol, 430, pp.2590~2611 (2018)
8. Trougakos IP, "Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications", J. Biomed. Sci, 28, pp.9~ (2021)
9. Gorbalenya AE, "Nidovirales : evolving the largest RNA virus genome", Virus Res, 117, pp.17~37 (2006)
10. Yoshimoto FK, "The proteins of severe acute respiratory syndrome coronavirus-2(SARS CoV-2 or n-COV19), the cause of COVID-19", Protein J, 39, pp.198~216 (2020)
11. Ashour HM, "Insights into the recent 2019 novel coronavirus(SARS-CoV-2)in light of past human coronavirus outbreaks", Pathogens, 9, pp.186~ (2020)
12. Perlman S, "Coronaviruses post-SARS : update on replication and pathogenesis", Nat. Rev. Microbiol, 7, pp.439~450 (2009)
13. Forni D, "Molecular evolution of human coronavirus genomes", Trends Microbiol, 25, pp.35~48 (2017)
14. Cunningham CH, "Cultivation of the virus of infectious bronchitis of chickens in embryonated chicken eggs", Am. J. Vet. Res, 8, pp.209~212 (1947)
15. Cheever FS, "A murine virus(JHM)causing disseminated encephalomyelitis with extensive destruction of myelin", J. Exp. Med, 90, pp.181~210 (1949)
16. McIntosh K, "Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease", Proc. Natl. Acad. Sci. USA, 57, pp.933~940 (1967)
17. Hamre D, "A new virus isolated from the human respiratory tract", Proc. Soc. Exp. Biol. Med, 121, pp.190~193 (1966)
18. Xu RH, "Epidemiologic clues to SARS origin in China", Emerg. Infect. Dis, 10, pp.1030~1037 (2004)
19. Zaki AM, "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia", N. Engl. J. Med, 367, pp.1814~1820 (2012)
20. Tao Y, "Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history", J. Virol, 91, pp.e01953~16 (2017)
21. Shang J, "Structural basis of receptor recognition by SARS-CoV-2", Nature, 581, pp.221~224 (2020)
22. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
23. Wu K, "Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor", Proc. Natl. Acad. Sci. U SA, 106, pp.19970~19974 (2009)
24. Li W, "Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2", EMBO J, 24, pp.1634~1643 (2005)
25. Reguera J, "Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies", PLoS Pathog, 8, pp.e1002859~ (2012)
26. Delmas B, "Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV", Nature, 357, pp.417~420 (1992)
27. Bonavia A, "Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E", J. Virol, 77, pp.2530~2538 (2003)
28. Raj VS, "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC", Nature, 495, pp.251~254 (2013)
29. Lu G, "Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26", Nature, 500, pp.227~231 (2013)
30. Jackson CB, "Mechanisms of SARS-CoV-2 entry into cells", Nat. Rev. Mol. Cell Biol, 23, pp.3~20 (2022)
31. Hoffmann M, "Priming time: How cellular proteases arm coronavirus spike proteins", pp.71~98 (2018), Springer International Publishing
32. Millet JK, "Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells", Virology, 517, pp.3~8 (2018)
33. Millet JK, "Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein", Proc. Natl. Acad. Sci. USA, 111, pp.15214~15219 (2014)
34. Hoffmann M, "A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells", Mol. Cell, 78, pp.779~784 (2020)
35. Takeda M, "Proteolytic activation of SARS-CoV-2 spike protein", Microbiol. Immunol, 66, pp.15~23 (2022)
36. Shulla A, "A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry", J. Virol, 85, pp.873~882 (2011)
37. Matsuyama S, "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2", J. Virol, 84, pp.12658~12664 (2010)
38. Shirato K, "Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2", J. Virol, 87, pp.12552~12561 (2013)
39. Limburg H, "TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes", J. Virol, 93, pp.e00649~19 (2019)
40. Zhao MM, "Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies", Cell Discov, 8, pp.53~ (2022)
41. Ou T, "Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2", PLoS Pathog, 17, pp.e1009212~ (2021)
42. Bayati A, "SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis", J. Biol. Chem, 296, pp.100306~ (2021)
43. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
44. "racking SARS-CoV-2 variants" (2022)[URL]
45. Magazine N, "Mutations and evolution of the SARS-CoV-2 spike protein", Viruses, 14, pp.640~ (2022)
46. McCallum M, "N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2", Cell, 184, pp.2332~2347 (2021)
47. Gobeil SM, "Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity", Science, 373, pp.eabi6226~ (2021)
48. Hikmet F, "The protein expression profile of ACE2 in human tissues", Mol. Syst. Biol, 16, pp.e9610~ (2020)
49. Ziegler CGK, "SARS-CoV-2 receptor ACE2 is an interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues", Cell, 181, pp.1016~1035 (2020)
50. Liu J, "SARS-CoV-2 cell tropism and multiorgan infection", Cell Discov, 7, pp.17~ (2021)
51. Xiao F, "Evidence for gastrointestinal infection of SARS-CoV-2", Gastroenterology, 158, pp.1831~1833 (2020)[DOI]
52. Sun J, "Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient", Emerg. Microbes Infect, 9, pp.991~993 (2020)
53. Gabarre P, "Acute kidney injury in critically ill patients with COVID-19", Intensive Care Med, 46, pp.1339~1348 (2020)
54. Salamanna F, "Body localization of ACE-2 : On the trail of the Keyhole of SARS-CoV-2", Front. Med(Lausanne), 7, pp.594495~ (2020)
55. Eslami N, "SARS-CoV-2 : receptor and co-receptor tropism probability", Curr. Microbiol, 79, pp.133~ (2022)
56. van der Velden VH, "Expression of aminopeptidase N and dipeptidyl peptidase IV in the healthy and asthmatic bronchus", Clin. Exp. Allergy, 28, pp.110~120 (1998)
57. Kindler E, "Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential", mBio, 4, pp.e00611~00612 (2013)
58. Lambeir AM, "Dipeptidyl-peptidase IV from bench to bedside : an update on structural properties, functions, and clinical aspects of the enzyme DPP IV", Crit. Rev. Clin. Lab. Sci, 40, pp.209~294 (2003)
59. Subissi L, "One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities", Proc. Natl. Acad. Sci. USA, 111, pp.3900~3909 (2014)
60. te Velthuis AJ, "The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent", Nucleic. Acids Res, 38, pp.203~214 (2010)
61. Ahn DG, "Biochemical characterization of a recombinant SARS coronavirus nsp12 RNAdependent RNA polymerase capable of copying viral RNA templates", Arch. Virol, 157, pp.2095~2104 (2012)
62. Kirchdoerfer RN, "Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors", Nat. Commun, 10, pp.2342~ (2019)
63. Bouvet M, "RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10", nsp14 exoribonuclease complex, 2012, pp.109, 9372~9377
64. Bouvet M, "Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes", J. Biol. Chem, 289, pp.25783~25796 (2014)
65. Yin W, "Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir", Science, 368, pp.1499~1504 (2020)
66. Hillen HS, "Structure of replicating SARS-CoV-2 polymerase", Nature, 584, pp.154~156 (2020)
67. Naydenova K, "Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP", Proc. Natl. Acad. Sci. USA, 118, pp.e2021946118~ (2021)
68. Nunziata Maio, "Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets", Science, 373(6551), pp.236~241 (2021), American Association for the Advancement of Science (AAAS)[DOI]
69. Riccio AA, "Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors", J. Biol. Chem, 298, pp.101518~ (2022)
70. Czarna A, "Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity", Structure, 30, pp.1050~5041 (2022)[DOI]
71. Nicholas H. Moeller, "Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN", Proceedings of the National Academy of Sciences, 119(9) (2022), Proceedings of the National Academy of Sciences[DOI]
72. Rona G, "The NSP14", NSP10 RNA repair complex as a Pan-coronavirus therapeutic target, 2022, pp.29, 285~292
73. Eckerle LD, "High fidelity of murine hepatitis virus replication is decreased in nsp14exoribonuclease mutants", J. Virol, 81, pp.12135~12144 (2007)
74. Eckerle LD, "Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing", PLoS Pathog, 6, pp.e1000896~ (2010)
75. Ogando NS, "The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2", J. Virol, 94, pp.e01246~20 (2020)
76. Brierley I, "Characterization of an efficient coronavirus ribosomal frameshifting signal : requirement for an RNA pseudoknot", Cell, 57, pp.537~547 (1989)
77. Plant EP, "The role of programmed-1 ribosomal frameshifting in coronavirus propagation", Front. Biosci, 13, pp.4873~4881 (2008)
78. Plant EP, "Altering SARS coronavirus frameshift efficiency affects genomic and subgenomic RNA production", Viruses, 5, pp.279~294 (2013)
79. Kelly JA, "Structural and functional conservation of the programmed-1 ribosomal frameshift signal of SARS coronavirus 2(SARS-CoV-2)", J. Biol. Chem, 295, pp.10741~10748 (2020)
80. Ahn DG, "A Novel Frameshifting inhibitor having antiviral activity against zoonotic coronaviruses", Viruses, 13, pp.1639~ (2021)
81. Plant EP, "A three-stemmed mRNA pseudoknot in the SARS coronavirus frameshift signal", PLoS Biol, 3, pp.e172~ (2005)
82. Irigoyen N, "High-resolution analysis of coronavirus gene expression by RNA sequencing and ribosome profiling", PLoS Pathog, 12, pp.e1005473~ (2016)
83. Wacker A, "Secondary structure determination of conserved SARS-CoV-2 RNA elements by NMR spectroscopy", Nucleic Acids Res, 48, pp.12415~12435 (2020)
84. Christina Roman, "The SARS-CoV-2 Programmed −1 Ribosomal Frameshifting Element Crystal Structure Solved to 2.09 Å Using Chaperone-Assisted RNA Crystallography", ACS Chemical Biology, 16(8), pp.1469~1481 (2021), American Chemical Society (ACS)[DOI]
85. Zhang K, "Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome", Nat. Struct. Mol. Biol, 28, pp.747~754 (2021)
86. HaniffHS, "Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera(RIBOTAC)degraders", ACS Cent. Sci, 6, pp.1713~1721 (2020)
87. Munshi S, "Identifying inhibitors of-1 programmed ribosomal frameshifting in a broad spectrum of coronaviruses", Viruse, 14, pp.177~ (2022)
88. Sun Y, "Restriction of SARS-CoV-2 replication by targeting programmed-1 ribosomal frameshifting", Proc. Natl. Acad. Sci. USA, 118, pp.e2023051118~ (2021)
89. Bussani R, "Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology", EBioMedicine, 61, pp.103104~ (2020)
90. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N. Engl. J. Med, 382, pp.727~733 (2020)
91. Buchrieser J, "Syncytia formation by SARS-CoV-2-infected cells", EMBO J, 40, pp.e107405~ (2021)
92. Zhu N, "Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells", Nat. Commun, 11, pp.3910~ (2020)
93. WolffG, "A molecular pore spans the double membrane of the coronavirus replication organelle", Science, 369, pp.1395~1398 (2020)
94. Ren Y, "The ORF3a protein of SARS-CoV-2 induces apoptosis in cells", Cell. Mol. Immunol, 17, pp.881~883 (2020)
95. Freundt EC, "The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death", J. Virol, 84, pp.1097~1109 (2010)
96. Law PTW, "The 3a protein of severe acute respiratory syndromeassociated coronavirus induces apoptosis in Vero E6 cells", J. Gen. Virol, 86, pp.1921~1930 (2005)
97. Li F, "SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K", AKT, Biochim. Biophys. Acta Mol. Basis Dis, pp.2021, 1867[DOI]
98. Rashid F, "The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta", Virus Res, 296, pp.198350~ (2021)
99. Shang C, "SARS-CoV-2 causes mitochondrial dysfunction and mitophagy impairment", Front. Microbiol, 12, pp.780768~ (2021)
100. Meyer K, "SARS-CoV-2 spike protein induces paracrine senescence and leukocyte adhesion in endothelial cells", J. Virol, 95, pp.e0079421~ (2021)
101. Evangelou K, "Pulmonary infection by SARS-CoV-2induces senescence accompanied by an inflammatory phenotype in severe COVID-19 : possible implications for viral mutagenesis", Eur. Respir. J, 60, pp.2102951~ (2022)
102. Zhu L, "Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes", Cell Metab, 31, pp.1068~1077 (2020)[DOI]
103. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
104. Cummings MJ, "Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City : a prospective cohort study", Lancet, 395, pp.1763~1770 (2020)
105. Tang X, "SARS-CoV-2 infection induces beta cell transdifferentiation", Cell Metab, 33, pp.1577~1591 (2021)[DOI]
106. Fung TS, "Coronavirus infection, ER stress, apoptosis and innate immunity", Front. Microbiol, 5, pp.296~ (2014)
107. Bull JJ, "Theory and empiricism in virulence evolution", PLoS Pathog, 10, pp.e1004387~ (2014)
108. Xia S, "Middle East respiratory syndrome coronavirus(MERS-CoV)entry inhibitors targeting spike protein", Virus Res, 194, pp.200~210 (2014)
109. Wu C, "Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods", Acta Pharm. Sin. B, 10, pp.766~788 (2020)
110. Simmons G, "Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry", Proc. Natl. Acad. Sci. USA, 102, pp.11876~11881 (2005)
111. Kawase M, "Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry", J. Virol, 86, pp.6537~6545 (2012)
112. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2spike glycoprotein", Cell, 181, pp.281~292 (2020)[DOI]
113. Yang Y, "Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus", Proc. Natl. Acad. Sci. USA, 111, pp.12516~12521 (2014)
114. Belouzard S, "Mechanisms of coronavirus cell entry mediated by the viral spike protein", Viruses, 4, pp.1011~1033 (2012)
115. Li F, "Structure, function, and evolution of coronavirus spike proteins", Annu. Rev. Virol, 3, pp.237~261 (2016)
116. Schoeman D, "Coronavirus envelope protein : current knowledge", Virol. J, 16, pp.69~ (2019)
117. DeDiego ML, "Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis", PLoS Pathog, 7, pp.e1002315~ (2011)
118. Nieto-Torres JL, "Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis", PLoS Pathog, 10, pp.e1004077~ (2014)
119. Kamitani W, "Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation", Proc. Natl. Acad. Sci. USA, 103, pp.12885~12890 (2006)
120. Narayanan K, "Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells", J. Virol, 82, pp.4471~4479 (2008)
121. Russo LC, "The SARS-CoV-2 Nsp3 macrodomain reverses PARP9", DTX3L-dependent ADP-ribosylation induced by interferon signaling, 2021, pp.297, 101041~
122. Forni D, "Extensive positive selection erives the evolution of nonstructural proteins in lineage C betacoronaviruses", J. Virol, 90, pp.3627~3639 (2016)
123. Shin D, "Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity", Nature, 587, pp.657~662 (2020)
124. Au-Yeung N, "Transcriptional and chromatin regulation in interferon and innate antiviral gene expression", Cytokine Growth Factor Rev, 44, pp.11~17 (2018)
125. Huangfu WC, "Ubiquitination-dependent regulation of signaling receptors in cancer", Genes Cancer, 1, pp.725~734 (2010)
126. Akutsu M, "Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains", Proc. Natl. Acad. Sci. USA, 108, pp.2228~2233 (2011)
127. Andrew AJ, "The formation of cysteine-linked dimers of BST-2", tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu, 2009, pp.6, 80~
128. Taylor JK, "Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference", J. Virol, 89, pp.11820~11833 (2015)
129. Thorne LG, "SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation", EMBO J, 40, pp.e107826~ (2021)
130. Bortolotti D, "TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection", Microorganisms, 9, pp.1820~ (2021)
131. Xagorari A, "Toll-like receptors and viruses : induction of innate antiviral immune responses", Open Microbiol. J, 2, pp.49~59 (2008)
132. Scheuplein VA, "High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus", J. Virol, 89, pp.3859~3869 (2015)
133. Cervantes-Barragan L, "Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon", Blood, 109, pp.1131~1137 (2007)
134. Mdkhana B, "Nucleic acid-sensing pathways during SARS-CoV-2 infection : Expectations versus reality", J. Inflamm. Res, 14, pp.199~216 (2021)
135. Zhao Z, "An enlightening role for cytokine storm in coronavirus infection", Clin. Immunol, 222, pp.108615~ (2021)
136. Wang J, "Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection : Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts", J. Leukoc Biol, 108, pp.17~41 (2020)
137. Beyer DK, "Mechanisms of antiviral immune evasion of SARS-CoV-2", J. Mol. Biol, 434, pp.167265~ (2022)
138. Park A, "Type I and Type III interferons-Induction, signaling, evasion, and application to combat COVID-19", Cell Host Microbe, 27, pp.870~878 (2020)
139. Oudshoorn D, "Expression and cleavage of middle east respiratory syndrome coronavirus nsp3-4 polyprotein induce the formation of double-membrane vesicles that mimic those associated with coronaviral RNA replication", mBio, 8, pp.e01658~17 (2017)
140. Angelini MM, "Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles", mBio, 4, pp.e00524~13 (2013)
141. Klein S, "SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography", Nat. Commun, 11, pp.5885~ (2020)
142. Li JY, "Innate immunity evasion strategies of highly pathogenic coronaviruses : SARS-CoV, MERS-CoV, and SARS-CoV-2", Front. Microbiol, 12, pp.770656~ (2021)
143. Chang LJ, "NSP16 2'-O-MTase in coronavirus pathogenesis : Possible prevention and treatments strategies", Viruses, 13, pp.538~ (2021)
144. Chen Y, "Functional screen reveals SARS coronavirus nonstructural protein nsp14as a novel cap N7 methyltransferase", Proc. Natl. Acad. Sci. USA, 106, pp.3484~3489 (2009)
145. Viswanathan T, "Structural basis of RNA cap modification by SARS-CoV-2", Nat. Commun, 11, pp.3718~ (2020)
146. Onomoto K, "Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity", PLoS One, 7, pp.e43031~ (2012)
147. Nakagawa K, "Inhibition of stress granule formation by middle east respiratory syndrome coronavirus 4a accessory protein facilitates viral translation, leading to efficient virus replication", J. Virol, 92, pp.e00902~18 (2018)
148. Gao B, "Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication", PLoS Pathog, 17, pp.e1008690~ (2021)
149. Zheng ZQ, "SARS-CoV-2 nucleocapsid protein impairs stress granule formation to promote viral replication", Cell Discov, 7, pp.38~ (2021)
150. Chen K, "SARS-CoV-2 Nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-beta production", Viruses, 13, pp.47~ (2020)
151. Michalska A, "A positive feedback amplifier circuit that regulates interferon(IFN)-stimulated gene expression and controls type I and type II IFN responses", Front. Immunol, 9, pp.1135~ (2018)
152. Yang X, "Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease", J. Gen. Virol, 95, pp.614~626 (2014)
153. Devaraj SG, "Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus", J. Biol. Chem, 282, pp.32208~32221 (2007)
154. Frieman M, "Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling", J. Virol, 83, pp.6689~6705 (2009)
155. Xia H, "Evasion of Type I interferon by SARS-CoV-2", Cell Rep, 33, pp.108234~ (2020)
156. Yang Y, "Middle east respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets", Sci. Rep, 5, pp.17554~ (2015)
157. Gao X, "Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70suggests unusual virus-host interactions", Nat. Commun, 12, pp.2843~ (2021)
158. Hayn M, "Systematic functional analysis of SARS-CoV-2proteins uncovers viral innate immune antagonists and remaining vulnerabilities", Cell Rep, 35, pp.109126~ (2021)
159. Minakshi R, "The SARS coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor", PLoS One, 4, pp.e8342~ (2009)
160. Miorin L, "SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling", Proc. Natl. Acad. Sci. USA, 117, pp.28344~28354 (2020)
161. Kopecky-Bromberg SA, "Severe acute respiratory syndrome coronavirus open reading frame(ORF)3b, ORF 6, and nucleocapsid proteins function as interferon antagonists", J. Virol, 81, pp.548~557 (2007)
162. Nalbandian A, "Post-acute COVID-19 syndrome", Nat. Med, 27, pp.601~615 (2021)
163. Brodin P, "Studying severe long COVID to understand post-infectious disorders beyond COVID-19", Nat. Med, 28, pp.879~882 (2022)
164. Cevik M, "SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness : a systematic review and meta-analysis", Lancet Microbe, 2, pp.13~22 (2021)
165. Arons MM, "Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility", N. Engl. J. Med, 382, pp.2081~2090 (2020)
166. Park WB, "Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection", Int. J. Infect. Dis, 72, pp.8~10 (2018)
167. Oh MD, "Viral load kinetics of MERS coronavirus infection", N. Engl. J. Med, 375, pp.1303~1305 (2016)
168. Xu D, "Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase", Eur. J. Clin. Microbiol. Infect. Dis, 24, pp.165~171 (2005)
169. Liu W, "Long-term SARS coronavirus excretion from patient cohort, China", Emerg. Infect. Dis, 10, pp.1841~1843 (2004)
170. Christensen BB, "Laboratory diagnosis for SARS-CoV-2 infection", Infect. Dis. Clin. North Am, 36, pp.327~347 (2022)
171. Dalia Arostegui KC, "Persistent SARS-CoV-2nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3 months after acute infection", JPGN Rep, 3, pp.e152~ (2022)
172. Wang X, "Persistence of intestinal SARS-CoV-2 infection in patients with COVID-19 leads to re-admission after pneumonia resolved", Int. J. Infect. Dis, 95, pp.433~435 (2020)
173. Chan PK, "Persistent infection of SARS coronavirus in colonic cells in vitro", J. Med. Virol, 74, pp.1~7 (2004)
174. Pacciarini F, "Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein", J. Virol, 82, pp.5137~5144 (2008)
175. Mizutani T, "Mechanisms of establishment of persistent SARS-CoV-infected cells", Biochem. Biophys. Res. Commun, 347, pp.261~265 (2006)
176. Lee S, "Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells", Emerg. Microbes Infect, 9, pp.2169~2179 (2020)
177. Kanwugu ON, "HIV", SARS-CoV-2 coinfection : A global perspective, 2021, pp.93, 726~732
178. Geretti AM, "Outcomes of coronavirus disease 2019(COVID-19)related hospitalization among people with human immunodeficiency virus(HIV)in the ISARIC World Health Organization(WHO)clinical characterization protocol(UK) : A prospective observational study", Clin. Infect. Dis, 73, pp.e2095~ (2021)[DOI]
179. Davies MA, "HIV and risk of COVID-19 death: a population cohort study from the Western cape province, South Africa", medRxiv (2020)[DOI]
180. Swets MC, "SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses", Lancet, 399, pp.1463~1464 (2022)
181. F Karim MM, "Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection", medRxiv (2021)[DOI]
182. Qureshi AI, "Reinfection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in patients undergoing serial laboratory testing", Clin. Infect. Dis, 74, pp.294~300 (2022)
183. Nguyen NN, "SARS-CoV-2 reinfection and COVID-19 severity", Emerg. Microbes Infect, 11, pp.894~901 (2022)
184. Baang JH, "Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient", J. Infect. Dis, 223, pp.23~27 (2021)
185. Choi B, "Persistence and evolution of SARS-CoV-2 in an immunocompromised host", N. Engl. J. Med, 383, pp.2291~2293 (2020)
186. Dan Frampton, "Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study", The Lancet Infectious Diseases, 21(9), pp.1246~1256 (2021), Elsevier BV[DOI]
187. Nuno R. Faria, "Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil", Science, 372(6544), pp.815~821 (2021), American Association for the Advancement of Science (AAAS)[DOI]
188. Lorenzo-Redondo R, "A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways", EBioMedicine, 62, pp.103112~ (2020)
189. Zhao S, "Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK : an early data-driven analysis", J. Travel Med. 2, 8, pp.taab001~ (2021)
190. Davies NG, "Estimated transmissibility and impact of SARSCoV-2 lineage B.1.1.7 in England", Science, 372, pp.eabg3055~ (2021)
191. Kim YJ, "The impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 pseudovirus", Viruses, 13, pp.633~ (2021)
192. Deng X, "Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant", Cell, 184, pp.3426~3437 (2021)
193. Yao H, "Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo", Cell Discov, 6, pp.76~ (2020)
194. Li Q, "The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity", Cell, 182, pp.1284~1294 (2020)
195. Young BE, "Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes : An observational study", EBioMedicine, 66, pp.103319~ (2021)
196. Stauft CB, "The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters", Virology, 556, pp.96~100 (2021)
197. Hofmann H, "Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry", Proc. Natl. Acad. Sci. USA, 102, pp.7988~7993 (2005)
198. Yeager CL, "Human aminopeptidase N is a receptor for human coronavirus 229E", Nature, 357, pp.420~422 (1992)
199. Tresnan DB, "Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I", J. Virol, 70, pp.8669~8674 (1996)
200. Williams RK, "Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins", Proc. Natl. Acad. Sci. USA, 88, pp.5533~5536 (1991)

관련 논문AI추천